Clinical trial
SU5416 and Carboplatin to Treat Ovarian Cancer
NCT00006155 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006155 |
|---|---|
| Title | SU5416 and Carboplatin to Treat Ovarian Cancer |
| Official title | A Phase I Study of SU5416, an Antiangiogenesis Agent, in Combination With Carboplatin in Patients With Platinum-Refractory Ovarian Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fallopian Tube Neoplasm, Ovarian Cancer, Peritoneal Neoplasm |
| Intervention type | Drug |
| Interventions | SU5416 and carboplatin |
| Enrollment | 33 |
| Start date | Aug 1, 2000 |
| Completion | Apr 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: